At 3 years after randomisation , 65 % of patients in the chemoimmunotherapy group were free of progression compared with 45 % in the chemotherapy group ( hazard ratio 056 [ 95 % CI 046-069 ] , p < 00001 ) ; 87 % were alive versus 83 % , respectively ( 067 [ 048-092 ] ; p = 001 ) .
